Are you still bullish on Genmab AS?
|By Ellen Johnson|
hype ideas genmab as healthcare biotechnology
We will cover Genmab AS in this post. What is Genmab AS Target Price Odds to finish over Current Price? Based on normal probability distribution, the odds of Genmab AS to move above current price in 30 days from now is under 4%. The Genmab AS probability density function shows the probability of Genmab AS Stock to fall within a particular range of prices over 30 days . Assuming 30 trading days horizon, Genmab AS has beta of 0.1316 . This indicates as returns on market go up, Genmab AS average returns are expected to increase less than the benchmark. However during bear market, the loss on holding Genmab AS will be expected to be much smaller as well. Additionally Genmab AS has an alpha of 0.388 implying that it can potentially generate 0.388% excess return over S&P 500 after adjusting for the inherited market risk (beta). Genmab AS dividends can provide a clue to current valuation of the stock. Genmab AS is not expected to issue dividends this year as it trying to preserve or re-invest any of the funds available for distribution to stakeholders.
On a scale of 0 to 100 Genmab AS holds performance score of 12. The company retains Market Volatility (i.e. Beta) of 0.1316 which attests that as returns on market increase, Genmab AS returns are expected to increase less than the market. However during bear market, the loss on holding Genmab AS will be expected to be smaller as well. . Although it is vital to follow to Genmab AS current price history, it is good to be conservative about what you can actually do with the information regarding equity current price movements. The philosophy towards determining future performance of any stock is to evaluate the business as a whole together with its past performance including all available fundamental and technical indicators. By evaluating Genmab AS technical indicators you can presently evaluate if the expected return of 0.4237% will be sustainable into the future. Please utilizes Genmab AS Coefficient Of Variation, Maximum Drawdown as well as the relationship between Maximum Drawdown and Skewness to make a quick decision on weather Genmab AS current trending patterns will revert.
This company currently falls under 'Large-Cap' category with current market capitalization of 10.91B. Genmab AS retains Downside Deviation of 2.25, Market Risk Adjusted Performance of 2.78 and Risk Adjusted Performance of 0.3075. The latest price spikes of Genmab AS may raise some interest from investors. The Stock closed today at a share price of 16.85 on 75300.000 in trading volume. The company directors and management were quite successful positioning the corporation components to exploit market volatility in February 2019. The stock standard deviation of daily returns for 30 days (very short) investing horizon is currently 2.3127. The current volatility is consistent with the ongoing market swings in December 2018 as well as with Genmab AS unsystematic, company specific events. Genmab AS makes 61.49m shares outstanding. Genmab AS is selling for 17.01. This is 1.10 percent increase. Today lowest is 16.85.
Genmab AS Current Market Performance
|Genmab AS Lifted to Hold at Zacks Investment Research - Fair...||03/29/2019|
|Sailingstone Capital Partners Increased Position in Eqt Well...||04/10/2019|
|Genmab Announces Data to be Presented at 2019 ASCO Annual Me...||04/17/2019|
|Aull Monroe Investment Management Holding in Intel Cut by 30...||05/03/2019|
|Ferguson Wellman Capital Management Has Lifted Johnson Johns...||05/06/2019|
|Ellen Johnson is a Member of Macroaxs Editorial Board. Ellen covers public companies in North America focusing primarily on valuation and volatility. Six years of experience in predictive investment analytics and risk management. View Profile|
|This headline from Macroaxis disseminated on 01/11/2019 added to the next day price reduction.The overall trading delta to closing price of the next trading day was 1.74% . The overall trading delta when the story was published to current closing price is 4.27% .|
Similar stores for Genmab AS
As Johnson Johnson Shares Declined, Kentucky Retirement Systems Insurance Trust Fund Lifted Stake Ballentine Partners Has Boosted Starbucks Holding by 845,696 as Share Price Rose CryptoCoinsTribuneKentucky Retirement Systems Insurance Trust Fund increased its stake in Johnson Johnson by 4.68 percent based on its latest 2018Q4 regulatory filing with ...
Camarda Financial Advisors Lowered Pfizer Stake by 324,435 Shares Declined Ronna Sue Cohen Continues to Hold Position in Paychex CryptoCoinsTribuneCamarda Financial Advisors Llc decreased its stake in Pfizer Inc by 27.2 percent based on its latest 2018Q4 regulatory filing with the SEC. Camarda Financial ...
Ferguson Wellman Capital Management Has Lifted Johnson Johnson Position by 14.67 Million as Share Value Declined Conocophillips Stock Value Rose While Wealthtrust Fairport Upped by 1. Million Its Stake CryptoCoinsTribuneFerguson Wellman Capital Management Inc increased its stake in Johnson Johnson by 58.79 percent based on its latest 2018Q4 regulatory filing with the SEC ...
Aull Monroe Investment Management Holding in Intel Cut by 303,600 as Market Value Rose As Johnson Johnson Stock Price Declined, Inverness Counsel Increased Position CryptoCoinsTribuneAull Monroe Investment Management Corp decreased its stake in Intel Corp by 6.1 percent based on its latest 2018Q4 regulatory filing with the SEC.
Genmab Announces Data to be Presented at 2019 ASCO Annual Meeting GlobeNewswireMedia Release Copenhagen, Denmark, April 17, 2019. 14 industry sponsored abstracts regarding Genmab programs selected for presentation at ASCO Annual ...
Sailingstone Capital Partners Increased Position in Eqt Wellington Shields Capital Management Has Increased Its Johnson Johnson Stake by 1.45 Million Standard RecorderSailingstone Capital Partners Llc increased its stake in Eqt Corp by 83.53 percent based on its latest 2018Q4 regulatory filing with the SEC. Sailingstone ...
Genmab AS Lifted to Hold at Zacks Investment Research Fairfield CurrentZacks Investment Research upgraded shares of Genmab AS from a strong sell rating to a hold rating in a report issued on Tuesday.
What Can The Quant Signals Tell Us About These Shares Genmab AS , Black Hills Corporation Augusta ReviewHere will take a quick scan of Earnings Yield information on shares of Genmab AS . Currently, the Earnings to Price is 0.020753, Earnings ...
As Raytheon Co Com New Share Value Rose, Sumitomo Life Insurance Company Increased Holding Abbvie Stock Price Declined While Pittenger Anderson Has Lowered Holding The MoveefySumitomo Life Insurance Company increased its stake in Raytheon Co Com New by 17.23 percent based on its latest 2018Q4 regulatory filing with the SEC.
Genmab AS Stock Rating Lowered by Zacks Investment Research Baseball Daily NewsGenmab AS was downgraded by Zacks Investment Research from a hold rating to a strong sell rating in a note issued to investors on ...
Guild Investment Management Has Trimmed Its Stake in Amazon Com by 310,914 Pfizer Holding Has Lifted by Verity Asset Management Inc The Hi New UlmGuild Investment Management Inc decreased its stake in Amazon Com Inc by 37.3 percent based on its latest 2018Q4 regulatory filing with the SEC.
Stock Review Investors Keen on Genmab AS as it Makes Headlines With Moves The Coin GuildGenmab AS has been in the news after the price of the stock hit 163.918 at the conclusion of the most recent close. The stock is traded on OTC in ...
|CME dips 0.74 percent despite market ascent|
May 21, 2019 by Achuva Shats
|The top 4 Large Growth stocks to keep in your portfolio in June 2019|
May 21, 2019 by Achuva Shats
|State Auto slips 1.06 percent albeit market build up|
May 21, 2019 by Vlad Skutelnik
|The Top 5 Furniture stocks to own in June 2019|
May 18, 2019 by Ellen Johnson
Cash per Share